chartexchange

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

PR Newswire | Oct 13, 2026 3:10 PM EDT

ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors. NEW YORK, Oct. 13, 2026...

Read original article